1xbet 등록 Pharmaceutical Co., Ltd.

• 1xbet 등록 developed the Major BCR-ABL mRNA Measurement Kit as an aid to diagnosis and monitoring of treatment effectiveness for chronic myeloid leukemia (CML) and health insurance in Japan now covers use of the kit.
• With approximately 11,000 CML patients 1xbet 등록 Japan and that number 1xbet 등록creas1xbet 등록g, and s1xbet 등록ce molecular-level assessment of treatment effectiveness has been limited 1xbet 등록 Japan, a test1xbet 등록g kit has been eagerly awaited 1xbet 등록 order to assess disease relapse and treatment effectiveness us1xbet 등록g an 1xbet 등록ternational standard value scale.
• The 1xbet 등록 Major BCR-ABL mRNA Measurement Kit is capable of measuring minutely residual leukemia cells at the molecular level, which is an international standard. The kit can be used to monitor treatment effectiveness or detect early relapse and thus is expected to contribute to the clinical management of CML.

1xbet 등록 Pharmaceutical Co., Ltd. announced that it received notification in Japan that as of April 1 insurance coverage is be provided for use of the 1xbet 등록 Major BCR-ABL mRNA Measurement Kit. The kit is an extracorporeal diagnostic pharmaceutical product meeting international standards for use as an aid to diagnose and monitor treatment effectiveness for chronic myeloid leukemia (CML).